Halozyme Therapeutics Inc (HALO)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 43% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Monthly momentum+13.8% over the past month+5
- 12-month trend+88% over the past year+6
- 52-week positionBreaking out to new 52-week highs+40
- QualityRevenue growing 41% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is **product/partnership momentum** — headlines emphasize Halozyme's ENHANZE platform gains and its competitive standing versus Merck, rather than a single earnings or M&A event. Continuation likelihood over the next few weeks is **moderate (~50–60%)**, since strong price momentum and new highs often persist short-term but are vulnerable to profit-taking after a ~90% yearly run. Informational only — not financial advice.
- TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataYahoo · 2026-10-26
- Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyYahoo · 2026-10-26
- RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallYahoo · 2026-10-26
- How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New HighsYahoo · 2026-10-23
- BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.Yahoo · 2026-10-23
Any AI summary is an interpretation of public news, not advice or a price target.